Walters HM et al. 33 has also reported increased serum IL-17A in patients with juvenile idiopathic arthritis who were treated by etanercept, a recombinant protein of soluble TNF receptor inhibiting TNF signaling. Here, IL17A is linked to juvenile idiopathic arthritis.